Bem vindo  

ACONTECE NA ABIFINA

Estudos sobre vacinas, drogas em desenvolvimento, drogas tradicionais, protocolos clínicos e suprimentos de IFAs para tratamento da Covid-19 (21/09/2020)

Acompanhe as atualizações! 

 

Receptor binding and priming of the spike protein of SARS-CoV-2 for membrane fusion

September 17, 2020 - SARS-CoV-2 infection is initiated by virus binding to ACE2 cell surface receptors1–4, followed by fusion of virus and cell membranes to release the virus genome into the cell

 

Painel mostra dados sobre medicamentos para Covid-19

17 de setembro de 2020 - Ferramenta traz informações do monitoramento sobre fabricação, importação e distribuição de fármacos utilizados em pacientes infectados pelo Sars-CoV-2

 

Sarilumab versus standard of care for the early treatment of COVID-19 pneumonia in hospitalized patients: SARTRE: a structured summary of a study protocol for a randomised controlled trial

September 16, 2020 - In some patients, acute, life-threatening respiratory injury produced by viruses such as SARS-CoV and other viral pneumonia are associated with an over-exuberant cytokine release

 

Identification of novel human USP2 inhibitor and its putative role in treatment of COVID-19 by inhibiting SARS-CoV-2 papain-like (PLpro) protease

September 13, 2020 - Human ubiquitin carboxyl-terminal hydrolase-2 (USP2) inhibitors, such as thiopurine analogs, have been reported to inhibit SARS-CoV papain-like proteases (PLpro)

 

Safety assessment of drug combinations used in COVID-19 treatment: in silico toxicogenomic data-mining approach

September 11, 2020 - Improvement of COVID-19 clinical condition was seen in studies where combination of antiretroviral drugs, lopinavir and ritonavir, as well as immunomodulant antimalaric, chloroquine/hydroxychloroquine together with the macrolide-type antibiotic, azithromycin, was used for patient's treatment

 

Convalescent plasma anti-SARS-CoV-2 spike protein ectodomain and receptor binding domain IgG correlate with virus neutralization

September 10, 2020 - The newly emerged severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) highlights the urgent need for assays that detect protective levels of neutralizing antibodies

 

Virtual screening of approved clinic drugs with main protease (3CLpro) reveals potential inhibitory effects on SARS-CoV-2

September 10, 2020 - 3CLpro is the main protease of the novel coronavirus (SARS-CoV-2) responsible for their intracellular duplication

 

The inorganic polymer, polyphosphate, blocks binding of SARS-CoV-2 spike protein to ACE2 receptor at physiological concentrations

September 6, 2020 - Inorganic polyphosphate (polyP) is a morphogenetically active and metabolic energy-delivering physiological polymer that is released from blood platelets

 

Potential Role of Acacia Senegal (Gum Arabic) as Immunomodulatory Agent among newly diagnosed COVID 19 Patients: A structured summary of a protocol for a randomised, controlled, clinical trial

September 5, 2020 - To investigate the potential efficacy of Acacia Senegal extract Gum Arabic (GA) supplementation as immunomodulatory and anti-inflammatory dietary intervention among newly diagnosed COVID 19 Sudanese patients

 

Terapia medicamentosa para infecções por coronavírus em humanos: revisão sistemática rápida

Setembro de 2020 - O objetivo deste trabalho foi avaliar efeitos de tratamentos medicamentosos para infecções por coronavírus

 

Hydroxychloroquine and Chloroquine Prescribing Patterns by Provider Specialty Following Initial Reports of Potential Benefit for COVID-19 Treatment - United States, January-June 2020

September 4, 2020 - Hydroxychloroquine and chloroquine are approved to treat autoimmune diseases and to prevent and treat malaria. Earlier this year, they were widely reported to be of potential benefit in the prevention and treatment of COVID-19; however, current data indicate that the potential benefits of these drugs do not outweigh their risks

 

Azithromycin in addition to standard of care versus standard of care alone in the treatment of patients admitted to the hospital with severe COVID-19 in Brazil (COALITION II): a randomised clinical trial

September 4, 2020 - The efficacy and safety of azithromycin in the treatment of COVID-19 remain uncertain. We assessed whether adding azithromycin to standard of care, which included hydroxychloroquine, would improve clinical outcomes of patients admitted to the hospital with severe COVID-19

 

Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia

September 4, 2020 - We developed a heterologous COVID-19 vaccine consisting of two components, a recombinant adenovirus type 26 (rAd26) vector and a recombinant adenovirus type 5 (rAd5) vector, both carrying the gene for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike glycoprotein (rAd26-S and rAd5-S)

 

The COVIRL002 Trial-Tocilizumab for management of severe, non-critical COVID-19 infection: A structured summary of a study protocol for a randomised controlled trial

September 3, 2020 - Tocilizumab is a humanized monoclonal antibody which targets and inhibits interleukin-6 (IL-6) and has demonstrated efficacy in treating diseases associated with hyper-inflammation

 

Effect of Hydrocortisone on Mortality and Organ Support in Patients With Severe COVID-19 The REMAP-CAP COVID-19 Corticosteroid Domain Randomized Clinical Trial

September 2, 2020 - Evidence regarding corticosteroid use for severe coronavirus disease 2019 (COVID-19) is limited

 

Phase 1–2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine

September 2, 2020 - NVX-CoV2373 is a recombinant severe acute respiratory syndrome coronavirus 2 (rSARS-CoV-2) nanoparticle vaccine composed of trimeric full-length SARS-CoV-2 spike glycoproteins and Matrix-M1 adjuvant

 

Favipiravir: A new and emerging antiviral option in COVID-19

September 2, 2020 - With over 16 million cases reported from across the globe, the SARS-CoV-2, a mere 125 microns in diameter, has left an indelible impact on our world

 

Statistical design of Phase II/III clinical trials for testing therapeutic interventions in COVID-19 patients

August 31, 2020 - Because of unknown features of the COVID-19 and the complexity of the population affected, standard clinical trial designs on treatments may not be optimal in such patient

 

COVID-19 drug repurposing: A review of computational screening methods, clinical trials, and protein interaction assays

August 30, 2020 -The situation of coronavirus disease 2019 (COVID‐19) pandemic is rapidly evolving, and medical researchers around the globe are dedicated to finding cures for the disease

 

Efficacy of tocilizumab treatment in severely ill COVID-19 patients

August 27, 2020 -The current coronavirus disease 2019 (COVID-19) pandemic induced by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has already caused a global increase in hospitalizations and deaths

 

Design and Evaluation of Anti-SARS-Coronavirus Agents Based on Molecular Interactions with the Viral Protease

August 27, 2020 - Three types of new coronaviruses (CoVs) have been identified recently as the causative viruses for the severe pneumonia-like respiratory illnesses, severe acute respiratory syndrome (SARS), Middle East respiratory syndrome (MERS), and corona-virus disease 2019 (COVID-19)

 

Role of antibody-dependent enhancement (ADE) in the virulence of SARS-CoV-2 and its mitigation strategies for the development of vaccines and immunotherapies to counter COVID-19

August 26, 2020 - Coronavirus disease-2019 (COVID-19) pandemic has become a global threat and death tolls are increasing worldwide

 

The effect of prostacyclin (Iloprost) infusion at a dose of 1 ng/kg/min for 72 hours compared to placebo in mechanically ventilated patients with COVID-19: A structured summary of a study protocol for a randomized controlled trial

August 26, 2020 - To investigate the effect of continuous infusion of the potential endothelial cytoprotective agent prostacyclin (Iloprost) 1 ng/kg/min vs. placebo for 72 hours on pulmonary endotheliopathy in mechanically ventilated COVID-19 patients

 

High dose dexamethasone treatment for Acute Respiratory Distress Syndrome secondary to COVID-19: a structured summary of a study protocol for a randomised controlled trial

August 26, 2020 - The aim of this study is to explore the effectiveness and safety of high dose dexamethasone treatment for Acute Respiratory Distress Syndrome secondary to SARS-Cov-2 pneumonia

 

Dynamics of the ACE2–SARS-CoV-2/SARS-CoV spike protein interface reveal unique mechanisms

August 26, 2020  - The coronavirus disease 2019 (COVID-19) pandemic, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is a major public health concern

 

Recent advances in therapeutic modalities and vaccines to counter COVID-19/SARS-CoV-2

August 26, 2020  - The novel coronavirus disease (COVID-19) caused by Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) has rapidly spread across the world

 

Role of antibody-dependent enhancement (ADE) in the virulence of SARS-CoV-2 and its mitigation strategies for the development of vaccines and immunotherapies to counter COVID-19

August 26, 2020 - Coronavirus disease-2019 (COVID-19) pandemic has become a global threat and death tolls are increasing worldwide. The SARS-CoV-2 though shares similarities with SARS-CoV and MERS-CoV, immunopathology of the novel virus is not understood properly

 

COVID-19: Pathophysiology, treatment options, nanotechnology approaches, and research agenda to combating the SARS-CoV2 pandemic

August 23, 2020 -The recent corona virus disease (COVID-19) outbreak has claimed the lives of many around the world and highlighted an urgent need for experimental strategies to prevent, treat and eradicate the virus

 

Virtual screening and molecular dynamics study of approved drugs as inhibitors of spike protein S1 domain and ACE2 interaction in SARS-CoV-2

August 21, 2020 - The receptor binding domain (RBD) of spike protein S1 domain SARS-CoV-2 plays a key role in the interaction with ACE2, which leads to subsequent S2 domain mediated membrane fusion and incorporation of viral RNA into host cells

 

Interleukin-6 in Covid-19: A systematic review and meta-analysis

August 26, 2020 - Coronaviruses may activate dysregulated host immune responses. As exploratory studies have suggested that interleukin-6 (IL-6) levels are elevated in cases of complicated Covid-19, we undertook a systematic review and meta-analysis to assess the evidence in this field

 

Evolutionary and structural analyses of SARS-CoV-2 D614G spike protein mutation now documented worldwide

August 20, 2020 - The COVID-19 pandemic, caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), was declared on March 11, 2020 by the World Health Organization

 

An integrated drug repurposing strategy for the rapid identification of potential SARS-CoV-2 viral inhibitors

August 17, 2020 - The Coronavirus disease 2019 (COVID-19) is an infectious disease caused by the severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2)

 

Efficacy of Tocilizumab in Covid 19: A metanalysis of case series studies

August 15, 2020  - Characteristic feature of COVID-19 during its progression in severity is the cytokine storm (via interleukin-6, IL-6) which is responsible for secondary acute respiratory distress syndrome (ARDS) [4]

 

A single dose of an adenovirus-vectored vaccine provides protection against SARS-CoV-2 challenge

August 14, 2020 - The unprecedented coronavirus disease 2019 (COVID-19) epidemic has created a worldwide public health emergency, and there is an urgent need to develop an effective vaccine to control this severe infectious disease

 

Clinical characteristics and corticosteroids application of different clinical types in patients with corona virus disease 2019

August 13, 2020 - To describe the epidemiological and clinical characteristics of patients with Corona Virus Disease 2019 (COVID-19) in Beijing

 

A high-throughput neutralizing antibody assay for COVID-19 diagnosis and vaccine evaluation

August 13, 2020 - Virus neutralization remains the gold standard for determining antibody efficacy

 

Phase 1/2 study of COVID-19 RNA vaccine BNT162b1 in adults

August 12, 2020 - In March 2020, the World Health Organization (WHO) declared a pandemic of coronavirus disease 2019 (COVID-19), due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)1

 

Convalescent Plasma Therapy for COVID-19: State of the Art

August 12, 2020 - Convalescent plasma (CP) therapy has been used since the early 1900s to treat emerging infectious diseases; its efficacy was later associated with the evidence that polyclonal neutralizing antibodies can reduce the duration of viremia

 

Anthraquinone Derivatives as an Immune Booster and their Therapeutic Option Against COVID-19

August 08, 2020 - Anthraquinone derivatives are identified for their immune-boosting, anti-inflammatory, and anti-viral efficacy

 

Global multi-omics and systems pharmacological strategy unravel the multi-targeted therapeutic potential of natural bioactive molecules against COVID-19: An in silico approach

August 07, 2020 - Understanding the immunological behavior of COVID-19 cases at molecular level is essential for therapeutic development

 

A systematic review and meta-analysis of the efficacy and safety of western medicine routine treatment combined with Chinese herbal medicine in the treatment of COVID-19

August 07, 2020 - COVID-19 is a global public health emergency. At present, there is no highly effective medicine for the prevention and treatment of 2019-nCoV

 

A Rational Design of a Multi-Epitope Vaccine Against SARS-CoV-2 Which Accounts for the Glycan Shield of the Spike Glycoprotein

August 07, 2020 - The ongoing global health crisis caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), the virus which leads to Coronavirus Disease 2019 (COVID-19) has impacted not only the health of people everywhere, but the economy in nations across the world

 

Structural analysis of full-length SARS-CoV-2 spike protein from an advanced vaccine candidate

August 06, 2020 - Vaccine efforts against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) responsible for the current COVID-19 pandemic are focused on SARS-CoV-2 spike glycoprotein, the primary target for neutralizing antibodies

 

Anti-complement C5 therapy with eculizumab in three cases of critical COVID-19

August 06, 2020 - Respiratory failure and acute kidney injury (AKI) are associated with high mortality in SARS-CoV-2-associated Coronavirus disease 2019 (COVID-19)

 

Presidente assina Medida Provisória que garante produção de vacina contra a Covid-19

06 de Agosto de 2020 - Crédito orçamentário de R$ 1,9 bilhão viabilizará a aquisição e produção de 100 milhões de doses da vacina contra a doença, produzida pelo laboratório AtraZeneca e Universidade de Oxford

 

Single-cell analysis of two severe COVID-19 patients reveals a monocyte-associated and tocilizumab-responding cytokine storm

August 06, 2020 - Several studies show that the immunosuppressive drugs targeting the interleukin-6 (IL-6) receptor, including tocilizumab, ameliorate lethal inflammatory responses in COVID-19 patients infected with SARS-CoV-2

 

Mitochondrial-targeted ubiquinone: A potential treatment for COVID-19

August 5, 2020 - Immune dysregulation characterized by T cell exhaustion and high level of inflammatory cytokines is associated with severe COVID-19

 

A phase II, single-center, double-blind, randomized placebo-controlled trial to explore the efficacy and safety of intravenous melatonin in patients with COVID-19 admitted to the intensive care unit (MelCOVID study): a structured summary of a study protocol for a randomized controlled trial

August 05, 2020 - Primary objective: to evaluate the effect of intravenous melatonin (IVM) on mortality in adult patients admitted to the intensive care unit (ICU) with COVID-19

 

A novel receptor-binding domain (RBD)-based mRNA vaccine against SARS-CoV-2

August 05, 2020 - The pandemic of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) highlights the need to develop effective and safe vaccines

 

SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness

August 05, 2020 - A vaccine for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is needed to control the global coronavirus infectious disease (COVID-19) public health crisis

 

In vitro screening of a FDA approved chemical library reveals potential inhibitors of SARS-CoV-2 replication

August 04, 2020  - A novel coronavirus, named SARS-CoV-2, emerged in 2019 in China and rapidly spread worldwide

 

Neutralizing antibody against SARS-CoV-2 spike in COVID-19 patients, health care workers and convalescent plasma donors: a cohort study using a rapid and sensitive high-throughput neutralization assay

August 04, 2020 - Rapid and specific antibody testing is crucial for improved understanding, control, and treatment of COVID-19 pathogenesis

 

De novo design of ACE2 protein decoys to neutralize SARS-CoV-2

August 03, 2020 - We have developed a generalized computational design strategy to rapidly engineer de novo proteins that precisely recapitulate the protein surface targeted by biological agents, like viruses, to gain entry into cells

 

Structural and functional properties of SARS-CoV-2 spike protein: potential antivirus drug development for COVID-19

August 03, 2020 - Coronavirus disease 2019 is a newly emerging infectious disease currently spreading across the world. It is caused by a novel coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)

 

Identification of promising drug candidates against NSP16 of SARS-CoV-2 through computational drug repurposing study

August 03, 2020 - The recent outbreak of the SARS-CoV-2 virus leading to the disease COVID 19, a global pandemic has resulted in an unprecedented loss of life and economy worldwide

 

Identification of potential drug candidates to combat COVID-19: a structural study using the main protease (mpro) of SARS-CoV-2

August 03, 2020 - The recent outbreak of the SARS-CoV-2 virus leading to the disease COVID 19 has become a global pandemic that is spreading rapidly and has caused a global health emergency

 

Anthocyanin derivatives as potent inhibitors of SARS-CoV-2 main protease: An in-silico perspective of therapeutic targets against COVID-19 pandemic

August 03, 2020 - A new pathogen severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has spread worldwide and become pandemic with thousands new deaths and infected cases globally

 

Antirheumatic Disease Therapies for the Treatment of COVID-19: A Systematic Review and Meta-analysis

August 2, 2020 - Antirheumatic disease therapies have been used to treat coronavirus disease 2019 (COVID-19) and its complications. We conducted a systematic review and meta-analysis to describe the current evidence

 

Epidemiological and clinical characteristics of the COVID-19 epidemic in Brazil

July 31, 2020 - The first case of COVID-19 was detected in Brazil on 25 February 2020

 

Anti-SARS-CoV-2 activities in vitro of Shuanghuanglian preparations and bioactive ingredients

July 31, 2020 - Human infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes coronavirus disease 2019 (COVID-19) and there is no cure currently

 

Single-Dose Nirsevimab for Prevention of RSV in Preterm Infants

July 30, 2020 - Respiratory syncytial virus (RSV) is the most common cause of lower respiratory tract infection in infants, and a need exists for prevention of RSV in healthy infants

 

Classification of the present pharmaceutical agents based on the possible effective mechanism on the COVID-19 infection

July 30, 2020 - There are several types of research on the COVID-19 disease which have been conducting

 

Potential treatment methods targeting 2019-nCoV infection

July 28, 2020 - The novel coronavirus, 2019-nCoV, has quickly spread across the world and pose serious threat to public health because it can infect people very easily

 

Hypothesis: Pentoxifylline is a potential cytokine modulator therapeutic in COVID‐19 patients

July 26, 2020 - We propose a new hypothesis that the established drug pentoxifylline deserves attention as a potential repurposed therapeutic for COVID‐19

 

Development of a Multi-Antigenic SARS-CoV-2 Vaccine Using a Synthetic Poxvirus Platform

July, 2020 - Modied Vaccinia Ankara (MVA) is a highly attenuated poxvirus vector that is widely used to develop vaccines for infectious diseases and cancer

 

Sulfated polysaccharides effectively inhibit SARS-CoV-2 in vitro

July 24, 2020 - COVID-19, caused by the SARS-CoV-2 virus, has now spread worldwide with catastrophic human and economic impacts and currently has infected over 10 million people and killed over 500,000

 

Discovery of SARS-CoV-2 antiviral drugs through large-scale compound repurposing

July 24, 2020 - This is a PDF fle of a peer-reviewed paper that has been accepted for publication. Although unedited, the content has been subjected to preliminary formatting. 

 

Targeting SARS‐CoV‐2 RBD interface: a supervised computational data‐driven approach to identify potential modulators

July 23, 2020 - Coronavirus Disease 2019 (COVID‐19) has spread out as a pandemic threat affecting over 2 million people

 

Safety, tolerability, and clinical outcomes of hydroxychloroquine for hospitalized patients with coronavirus 2019 disease

July 23, 2020 - Severe acute respiratory coronavirus 2 (SARS-CoV-2) has caused a devastating worldwide pandemic. Hydroxychloroquine (HCQ) has in vitro activity against SARS-CoV-2, but clinical data supporting HCQ for coronavirus disease 2019 (COVID-19) are limited

 

Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19

July 23, 2020 - Hydroxychloroquine and azithromycin have been used to treat patients with coronavirus disease 2019 (Covid-19). However, evidence on the safety and efficacy of these therapies is limited.

 

Tocilizumab for severe COVID-19: a systematic review and meta-analysis

July 23, 2020 - This systemic review and meta-analysis aimed to assess the efficacy of tocilizumab for the treatment of severe coronavirus disease-2019 (COVID-19)

 

Ribavirin Therapy For Severe COVID-19: A Retrospective Cohort Study

July 23, 2020 - We aimed to compare ribavirin therapy for patients with severe COVID-19 with a supportive therapy only

 

Immunomodulatory effect of mesenchymal stem cells and mesenchymal stem-cell-derived exosomes for COVID-19 treatment

July 22, 2020 - The world has witnessed unimaginable damages at the hands of the coronavirus disease-19 (COVID-19) pandemic

 

Drugs targeting various stages of the SARS-CoV-2 life cycle: Exploring promising drugs for the treatment of Covid-19

July 22, 2020 - The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a positive-sense, single-stranded RNA virus that causes the potentially lethal Covid-19 respiratory tract infection

 

Potent neutralizing antibodies directed to multiple epitopes on SARS-CoV-2 spike

July 22, 2020 - The SARS-CoV-2 pandemic rages on with devasting consequences on human lives and the global economy

 

Rationale and evidence on the use of tocilizumab in COVID-19: a systematic review

July 20, 2020 - Tocilizumab is an IL-6 receptor-blocking agent proposed for the treatment of severe COVID-19

 

Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebocontrolled, phase 2 trial

July 20, 2020 - This is the first randomised controlled trial for assessment of the immunogenicity and safety of a candidate non-replicating adenovirus type-5 (Ad5)-vectored COVID-19 vaccine, aiming to determine an appropriate dose of the candidate vaccine for an efficacy study

 

Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial

July 20, 2020 - The pandemic of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) might be curtailed by vaccination

 

Dexamethasone in Hospitalized Patients with Covid-19 — Preliminary Report

July 17, 2020 - Coronavirus disease 2019 (Covid-19) is associated with diffuse lung damage. Glucocorticoids may modulate inflammation-mediated lung injury and thereby reduce progression to respiratory failure and death

 

Effects on QT interval of hydroxychloroquine associated with ritonavir/darunavir or azithromycin in patients with SARS-CoV-2 infection

July 16, 2020 - To evaluate the effects of an association therapy of hydroxychloroquine (HY) plus ritonavir/darunavir (RD) or azithromycin (AZ) on QTc intervals

 

Exploring an Integrative Therapy for Treating COVID-19: A Randomized Controlled Trial

July 16, 2020 - To develop a new Chinese medicine (CM)-based drug and to evaluate its safety and effect for suppressing acute respiratory distress syndrome (ARDS) in COVID-19 patients

 

Intermolecular interaction among Remdesivir, RNA and RNA-dependent RNA polymerase of SARS-CoV-2 analyzed by fragment molecular orbital calculation

July 15, 2020 - COVID-19, a disease caused by a new strain of coronavirus (SARS-CoV-2) originating from Wuhan, China, has now spread around the world, triggering a global pandemic, leaving the public eagerly awaiting the development of a specific medicine and vaccine

 

An mRNA Vaccine against SARS-CoV-2 — Preliminary Report

July 14, 2020 - The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in late 2019 and spread globally, prompting an international effort to accelerate development of a vaccine

 

Application prospect of polysaccharides in the development of anti-novel coronavirus drugs and vaccines

July 14, 2020 - Since the outbreak of the novel coronavirus disease COVID-19, caused by the SARS-CoV-2 virus, it has spread rapidly worldwide and poses a great threat to public health

 

The renin–angiotensin–aldosterone system: Role in pathogenesis and potential therapeutic target in COVID‐19

July 13, 2020 - Coronavirus disease 2019 (COVID‐19), caused by the SARS‐CoV‐2 novel coronavirus, has spread worldwide causing high fatality rates

 

A perspective on potential antibodydependent enhancement of SARS-CoV-2

July 13, 2020 - This is a PDF fle of a peer-reviewed paper that has been accepted for publication

 

An overview of the safety, clinical application and antiviral research of the COVID-19 therapeutics

July 13, 2020 - Since a novel coronavirus pneumonia outbreak in late December 2019, coronavirus disease -19 (COVID-19) epidemic has gradually spread worldwide, becoming a major public health event

 

Renin-Angiotensin System Blockade in COVID-19: Good, Bad, or Indifferent?

July 13, 2020 - Based on the observation that patients with hypertension appear to have adverse outcomes with coronavirus disease-2019 

 

Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19

July 12, 2020 - In a longitudinal analysis of SARS-CoV-2- infected people, Kreer et al. find highly potent neutralizing antibodies that use a broad spectrum of variable (V) genes and show low levels of somatic mutations

 

A molecular docking study repurposes FDA approved iron oxide nanoparticles to treat and control COVID-19 infection

July 12, 2020 - COVID-19, is a disease resulting from the SARS-CoV-2 global pandemic. Due to the current global emergency and the length of time required to develop specific antiviral agent(s) and a vaccine for SARS-CoV-2

 

Tocilizumab for treatment of mechanically ventilated patients with COVID-19

July 11, 2020 - Severe COVID-19 can manifest in rapid decompensation and respiratory failure with elevated inflammatory markers, consistent with cytokine release syndrome for which IL-6 blockade is approved treatment

 

Comparison of hydroxychloroquine, lopinavir/ritonavir, and standard of care in critically ill patients with SARS-CoV-2 pneumonia: an opportunistic retrospective analysis

July 11, 2020 - The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) outbreak is spreading worldwide.

 

Emerging pharmacological therapies for ARDS: COVID-19 and beyond

July 11, 2020 - Acute respiratory distress syndrome (ARDS) is the commonest form of acute severe hypoxemic respiratory failure in the critically ill

 

Control of SARS-CoV-2 infection in rituximab-treated neuroimmunological patients

July 11, 2020 - Individuals with autoimmune diseases, such as multiple sclerosis (MS) or neuromyelitis optica spectrum disorder (NMOSD), that require long-term immunosuppression are regarded as particularly vulnerable in the current COVID-19 pandemic

 

Bioinformatics analysis of epitope-based vaccine design against the novel SARS-CoV-2

July 10, 2020 - An outbreak of infection caused by SARS-CoV-2 recently has brought a great challenge to public health. Rapid identification of immune epitopes would be an efficient way to screen the candidates for vaccine development at the time of pandemic

 

Maior estudo sobre COVID-19 analisou proporção de anticorpos da população brasileira

10.07.2020 - O trabalho “Evolução da Prevalência de Infecção por Covid-19 no Brasil: Estudo de Base Populacional”, financiado pelo Ministério da Saúde e o maior já feito sobre a circulação do Sars-Cov-2 no país, foi concluído

 

Efficacy of Corticosteroids in Non-Intensive Care Unit Patients with COVID-19 Pneumonia from the New York Metropolitan region

July 10, 2020 - The role of systemic corticosteroid as a therapeutic agent for patients with COVID 19 pneumonia is controversial

 

COVID-19 and Mesenchymal Stem Cell Treatment; Mystery or Not

July 10, 2020 - On December 31, 2019, novel SARS-CoV2 spread from Wuhan China to more than 200 territories around world and the World Health Organization declared a COVID-19 pandemic on January 30, 2020

 

Characterization of heparin and severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) spike glycoprotein binding interactions

July 09, 2020 - - Severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) has resulted in a pandemic and continues to spread around the globe at an unprecedented rate

 

Self-amplifying RNA SARS-CoV-2 lipid nanoparticle vaccine candidate induces high neutralizing antibody titers in mice

July 09, 2020 - The spread of the SARS-CoV-2 into a global pandemic within a few months of onset motivates the development of a rapidly scalable vaccine

 

Effectiveness of Ivermectin as add-on Therapy in COVID-19 Management (Pilot Trial)

July 08, 2020 - To date no effective therapy has been demonstrated for COVID-19. In vitro, studies indicated that ivermectin (IVM) has antiviral effect

 

Renin-angiotensin-aldosterone system inhibitors and COVID-19 infection or hospitalization: a cohort study

July 07, 2020 - There are plausible mechanisms by which angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) may increase the risk of COVID-19 infection or affect disease severity

 

SARS-CoV-2, ACE2, and Hydroxychloroquine: Cardiovascular Complications, Therapeutics, and Clinical Readouts in the Current Settings

July 07, 2020 - The rapidly evolving coronavirus disease 2019 (COVID-19, caused by severe acute respiratory syndrome coronavirus 2- SARS-CoV-2), has greatly burdened the global healthcare system and led it into crisis in several countries

 

GPU-Accelerated Drug Discovery with Docking on the Summit Supercomputer: Porting, Optimization, and Application to COVID-19 Research

July 06, 2020 - Protein-ligand docking is an in silico tool used to screen potential drug compounds for their ability to bind to a given protein receptor within a drug-discovery campaign 

 

Discovery of Drug-like Ligands for the Mac1 Domain of SARS-CoV-2 Nsp3

July 06, 2020 - The Mac1 domain of the multifunctional SARS-CoV-2 non-structural protein 3 (nsp3) is a potential COVID-19 drug target because it is suspected to enhance the ability of the virus to evade the human immune system

 

Conserved Genomic Terminals of SARS-CoV-2 as Co-evolving Functional Elements and Potential Therapeutic Targets

July 06, 2020 - To identify features in the genome of the SARS-CoV-2 pathogen responsible for the COVID-19 pandemic that may contribute to its viral replication, host pathogenicity, and vulnerabilities, we investigated how and to what extent the SARS-CoV-2 genome sequence differs from other well-characterized human and animal coronavirus genomes

 

Safety and efficacy of anti-il6-receptor tocilizumab use in severe and critical patients affected by coronavirus disease 2019: a comparative analysis

July 06, 2020 - This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record


Structural features of coronavirus SARS-CoV-2 spike protein: Targets for vaccination

July 06, 2020 - Various human pathogenic viruses employ envelope glycoproteins for host cell receptor recognition and binding, membrane fusion and viral entry

 

Role of IgD in prevention and treatment of SARS CoV-2 infection “The Unknown Soldier"

July 05, 2020 - COVID-19 presents varied clinical features, ranging from asymptomatic, mild, to acute respiratory distress syndrome (ARDS)

 

Potential effective treatment for COVID-19: systematic review and meta-analysis of the severe infectious disease with convalescent plasma therapy

July 04, 2020 - Convalescent plasma (CP) has been used successfully to treat many types of infectious diseases, and it has shown initial effects in the treatment of the emerging 2019 coronavirus disease (COVID-19)


Corticosteroid therapy for patients with CoVID-19 pneumonia: a before-after study

July 04, 2020 - Anti-inflammatory drugs such as corticosteroids may beneficially modulate the host inflammatory response to CoVID-19 pneumonia

 

Update on therapeutic approaches and emerging therapies for SARS-CoV-2 virus

July 04, 2020 - The global pandemic of coronavirus disease 2019 (COVID-19), caused by novel severe acute respiratory syndrome coronavirus

 

Recent insights for the emerging COVID-19: drug discovery, therapeutic options and vaccine development

July 04, 2020 - SARS-CoV-2 has been marked as a highly pathogenic coronavirus of COVID-19 disease into the human population, causing over 5.5 million confirmed cases worldwide

 

A Perspective on Emerging Therapeutic Interventions for COVID-19

July 03, 2020 - Coronaviruses are enveloped positive-sense RNA viruses with an unusual large RNA genome and a unique replication mechanism, which are characterized by club-like spikes that protrude from their surface


Efficacy and safety of umifenovir for coronavirus disease 2019 (COVID‐19): A systematic review and meta‐analysis

July 03, 2020 - We conducted this systemic review and meta‐analysis in an attempt to evaluate the efficacy and safety of umifenovir in COVID‐19 

 

Phylogenetic Analysis and Structural Perspectives of RNA-Dependent RNA-Polymerase Inhibition from SARs-CoV-2 with Natural Products

July 03, 2020 - Most recently, an outbreak of severe pneumonia caused by the infection of SARS-CoV-2, a novel coronavirus first identified in Wuhan, China, imposes serious threats to public health

 

Microstructure, pathophysiology and potential therapeutics of COVID‐19: A comprehensive review

July 03, 2020 - This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the Version of Record

 

Turning the Tide: Natural Products and Natural-Product-Inspired Chemicals as Potential Counters to SARS-CoV-2 Infection

July 02, 2020 - The novel and highly pathogenic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which causes coronavirus disease 2019 (COVID-19), has become a continued focus of global attention due to the serious threat it poses to public health

 

A Network Medicine Approach to Investigation and Population-based Validation of Disease Manifestations and Drug Repurposing for COVID-19

July 02, 2020 - The global Coronavirus Disease 2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has led to unprecedented social and economic consequences

 

Whole Genome Analysis and Targeted Drug Discovery Using Computational Methods and High Throughput Screening Tools for Emerged Novel Coronavirus (2019-nCoV)

July 02, 2020 - A novel coronavirus designated as SARS-CoV-2 in February 2020 by World Health organization (WHO) was identified as main cause of SARS like pneumonia cases in Wuhan city in Hubei Province of China at the end of 2019

 

In silico Drug Repurposing to combat COVID-19 based on Pharmacogenomics of Patient Transcriptomic Data

June 30, 2020 - The ongoing global pandemic of coronavirus disease 2019 (COVID-19) continues to affect a growing number of populations in different parts of the world. In the current situation, drug repurposing is a viable strategy to combat COVID-19

 

O reposicionamento de fármacos como uma potencial estratégia para o tratamento da COVID-19

29 de junho de 2020 - No final de 2019 uma nova cepa de coronavírus foi descoberta na China, responsável por causar a doença COVID-19, caracterizada pela OMS como uma pandemia em março de 20207

 

Brasil entra em parceria para produção de vacina contra Covid-19

27 de Junho de 2020 - País receberá a transferência de tecnologia da tecnologia mais promissora contra a doença no mundo. Quando demonstrada segurança, serão 100 milhões de doses

 

Combating COVID-19 with integrated traditional Chinese and Western medicine in China

June 27, 2020 - COVID-19, an acute respiratory infection caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has spread throughout the world

 

The role of angiotensin-converting enzyme 2 in the pathogenesis of COVID-19: the villain or the hero?

June 27, 2020 - Angiotensin-converting enzyme 2 (ACE 2) is the entry receptor for the novel coronavirus SARS-CoV-2, the aetiological agent of COVID-19

 

Successful recovery from COVID-19 pneumonia after receiving baricitinib, tocilizumab, and remdesivir. A case report: Review of treatments and clinical role of computed tomography analysis

June 27, 2020 - The novel coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a pandemic, threatening global public health

 

Drug treatment of coronavirus disease 2019 (COVID-19) in Chin

June 27, 2020 - Since December 2019, the coronavirus disease 2019 (COVID-19) caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has spread throughout China as well as other countries

 

Convalescent Plasma Therapy in Coronavirus Disease 2019: a Case Report and Suggestions to Overcome Obstacles

June 26, 2020 - Coronavirus disease 2019 (COVID-19) is rapidly spreading around the world, causing much morbidity and mortality everywhere

 

Transcriptomic Signatures and Immunomodulatory Treatments for COVID-19 Patients

June 26, 2020 - Since December 2019, the novel coronavirus SARS-CoV-2 has infected over 9.0 million and led to death of over 472,000 people, damaging the world’s social and economic fabrics

 

SARS-CoV-2 Exoribonuclease (NSP14) As a Potential Therapeutic Target to Treat COVID-19

June 26, 2020 - Although the global health emergency caused by SARS-CoV-2 has led to unprecedented health and socioeconomic crisis, as of today neither an antiviral treatment has been approved for COVID-19, nor is a vaccine available

 

Glycans on the SARS-CoV-2 Spike Control the Receptor Binding Domain Conformation

June 26, 2020 - The glycan shield of the beta-coronavirus (β-CoV) Spike (S) glycoprotein provides protection from host immune responses, acting as a steric block to potentially neutralizing antibody responses

 

High-dose but not low-dose corticosteroids potentially delay viral shedding of patients with COVID-19

June 26, 2020 - Article PDF

 

Auxiliary role of mesenchymal stem cells as regenerative medicine soldiers to attenuate inflammatory processes of severe acute respiratory infections caused by COVID-19

June 25, 2020 - Acute respiratory infections as one of the most common problems of healthcare systems also can be considered as an important reason for worldwide morbidity and mortality from infectious diseases

 

Antiviral mechanisms of candidate chemical medicines and traditional Chinese medicines for SARS-CoV-2 infection

June 24, 2020 - The Coronavirus Disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has rapidly become a global pandemic

 

Tocilizumab in patients with severe COVID-19: a retrospective cohort study

June 24, 2020 - No therapy is approved for COVID-19 pneumonia. The aim of this study was to assess the role of tocilizumab in reducing the risk of invasive mechanical ventilation and death in patients with severe COVID-19 pneumonia who received standard of care treatment

 

In-hospital Use of Statins is Associated with a Reduced Risk of Mortality among Individuals with COVID-19

June 24, 2020 - Statins are lipid-lowering therapeutics with favorable anti-inflammatory profiles and have been proposed as an adjunct therapy for COVID-19. However, statins may increase the risk of SARS-CoV-2 viral entry by inducing ACE2 expression

 

Advantages of the Parent Nucleoside GS-441524 over Remdesivir for Covid-19 Treatment

June 23, 2020 - While remdesivir has garnered much hope for its moderate anti-Covid-19 effects, its parent nucleoside, GS-441524, has been overlooked. Pharmacokinetic analysis of remdesivir evidences premature serum hydrolysis

 

Structures of human antibodies bound to SARS-CoV-2 spike reveal common epitopes and recurrent features of antibodies

June 23, 2020 - Neutralizing antibody responses to coronaviruses mainly target the receptor-binding domain (RBD) of the trimeric spike

 

Treatment of Coronavirus Disease 2019 (COVID-19): Investigational Drugs and Other Therapies

June 22, 2020 - Coronavirus disease 2019 (COVID-19) is defined as illness caused by a novel coronavirus now called severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2; formerly called 2019-nCoV), which was first identified amid an outbreak of respiratory illness cases in Wuhan City, Hubei Province, China

 

nCOV-19 peptides mass fingerprinting identification, binding, and blocking of inhibitors flavonoids and anthraquinone of Moringa oleifera and hydroxychloroquine

June 22, 2020 - An rare pandemic of viral pneumonia occurs in December 2019 in Wuhan, China, which is now recognized internationally as Corona Virus Disease 2019 (COVID-19), the etiological agent classified as Severe Acute Respiratory Syndrome Corona Virus 2 (SARS-CoV-2)

 

Constituents of buriti oil (Mauritia flexuosa L.) like inhibitors of the SARS-Coronavirus main peptidase: an investigation by docking and molecular dynamics

June 22, 2020 - Statistics show alarming numbers of infected and killed in the world, caused by the Covid-19 pandemic, which still doesn’t have a specific treatment and effective in combating all efforts to seek treatments and medications against this disease


Autophagy and SARS-CoV-2 infection: Apossible smart targeting of the autophagy pathway

June 22, 2020 - The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) outbreak resulted in 5,993,317 confirmed cases worldwide with 365,394 confirmed deaths (as  of  May  29 th ,  2020, WHO)

 

Structure-based virtual screening and molecular dynamics simulation of SARS-CoV-2 Guanine-N7 methyltransferase (nsp14) for identifying antiviral inhibitors against COVID-19

June 22, 2020 - The recent pandemic caused by Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) calls the whole world into a medical emergency

 

Promising inhibitors of main protease of novel corona virus to prevent the spread of COVID-19 using docking and molecular dynamics simulation

June 22, 2020 - Coronavirus disease-2019 (COVID-19) is a global health emergency and the matter of serious concern, which has been declared a pandemic by WHO

 

Current status of COVID-19 therapies and drug repositioning applications

June 19, 2020 - The rapid and global spread of a new human coronavirus (SARS-CoV-2) has produced an immediate urgency to discover promising targets for treatment of COVID-19

 

Convergent antibody responses to SARS-CoV-2 in convalescent individuals

June 18, 2020 - During the COVID-19 pandemic, SARS-CoV-2 infected millions of people and claimed hundreds of thousands of lives

 

A narrative literature review on traditional medicine options for treatment of corona virus disease 2019 (COVID-19)

June 17, 2020 - Coronavirus disease 2019 (COVID-19) as a life-threatening disease is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that is accounted as global public health concern

 

Overview of therapeutic drug research for COVID-19 in China

June 17, 2020 - Since the outbreak of novel coronavirus pneumonia (COVID-19) in December 2019, more than 2,500,000 people worldwide have been diagnosed with SARS-CoV-2 as of April 22. In response to this epidemic, China has issued seven trial versions of diagnosis and treatment protocol for COVID-19

 

Boceprevir, GC-376, and calpain inhibitors II, XII inhibit SARS-CoV-2 viral replication by targeting the viral main protease

June 15, 2020 - A new coronavirus SARS-CoV-2, also called novel coronavirus 2019 (2019-nCoV), started to circulate among humans around December 2019, and it is now widespread as a global pandemic

 

The use of renin angiotensin system inhibitor on mortality in patients with coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis

June 14, 2020 - Coronavirus disease 2019, commonly known as COVID-19, is a raging global pandemic

 

Intracellular ABCB1 as a Possible Mechanism to Explain the Synergistic Effect of Hydroxychloroquine-Azithromycin Combination in COVID-19 Therapy

June 14, 2020 - The co-administration of hydroxychloroquine with azithromycin is proposed in COVID-19 therapy

 

Antiviral activity of the high-molecular-weight plant polysaccharides (Panavir(R))

June 14, 2020 - This short report is dedicated to the description of the wide antiviral and antibacterial activity of the immune-modulating agent Panavir(R)

 

Coronavirus breakthrough: dexamethasone is first drug shown to save lives

June 13, 2020 - In a large trial, a cheap and widely available steroid cut deaths by one-third among patients critically ill with COVID-19

 

Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial

June 13, 2020 - A vaccine to protect against COVID-19 is urgently needed. We aimed to assess the safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 (Ad5) vectored COVID-19 vaccine expressing the spike glycoprotein of a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) strain

 

Vaccination strategies to combat novel corona virus SARS-CoV-2

June 12, 2020 - The 2019-novel coronavirus disease (COVID-19) is caused by SARS-CoV-2 is transmitted from human to human has recently reported in China

 

Virtual screening, ADME/Tox predictions and the drug repurposing concept for future use of old drugs against the COVID-19

June 11, 2020 - The new Coronavirus (SARS-CoV-2) is the cause of a serious infection in the respiratory tract called COVID-19

 

Potential of coronavirus 3C-like protease inhibitors for the development of new anti-SARS-CoV-2 drugs: Insights from structures of protease and inhibitors

June 11, 2020 - Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), similar to SARS-CoV and the Middle East respiratory syndrome coronavirus (MERS-CoV), which belong to the same β-coronavirus group, induces sever acute respiratory disease, threatening human health

 

Prospects of Replication-Deficient Adenovirus Based Vaccine Development against SARS-CoV-2

June 10, 2020 - The current appearance of the new SARS coronavirus 2 (SARS-CoV-2) and it quickly spreading across the world poses a global health emergency

 

Broad-Spectrum Host-Based Antivirals Targeting the Interferon and Lipogenesis Pathways as Potential Treatment Options for the Pandemic Coronavirus Disease 2019 (COVID-19)

June 10, 2020 - The ongoing Coronavirus Disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) signals an urgent need for an expansion in treatment options

 

Aminoglycosides can be a better choice over macrolides in COVID-19 regimen: Plausible mechanism for repurposing strategy

June 10, 2020 - In the current COVID-19 pandemic, prioritizing the immunity enhancers is equally important to anti-virals

 

BCG vaccine protection from severe coronavirus disease 2019 (COVID-19)

June 09, 2020 - The bacillus Calmette−Guérin (BCG) vaccine, an attenuated Mycobacterium bovis (1), has been extensively used in national vaccination programs, as it confers cross-protection from Mycobacterium tuberculosis infection 

 

Statins as early therapy to mitigate COVID-19 (SARS-CoV-2)-associated ARDS and cytokine storm syndrome – time is of the essence

June 09, 2020 -While most coronavirus disease 2019 (COVID-19) infections run a benign course with recovery, the inexorable rise in case fatalities in several countries is grim testimony to the lack of effective therapies to arrest the course of severe infections

 

Vacina nacional de Bio-Manguinhos/Fiocruz para novo coronavírus entrará em estudo pré-clínico

09.06.2020 - Vacina nacional de Bio-Manguinhos/Fiocruz para novo coronavírus entrará em estudo pré-clínico. Projeto está pronto para avançar em estudos in vivo

 

EMA receives application for conditional authorisation of first COVID-19 treatment in the EU

June 08, 2020 - EMA has now received an application for conditional marketing authorisation (CMA) of the antiviral medicine remdesivir for the treatment of COVID-19 and has formally started its evaluation

 

α-glucosidase inhibitors as host-directed antiviral agents with potential for the treatment of COVID-19

June 08, 2020 - The ongoing COVID-19 pandemic, caused by SARS-CoV-2, has pushed the health systems of many countries to breaking point and precipitated social distancing measures that have crippled economic activities across the globe

 

Monoclonal antibody as a potential anti-COVID-19

June 04, 2020 - Coronavirus disease 2019 (COVID-19) is expanding rapidly, which made it as one of top priorities for scientists to develop novel treatment strategies

 

A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19

June 3, 2020 - Coronavirus disease 2019 (Covid-19) occurs after exposure to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). For persons who are exposed, the standard of care is observation and quarantine

 

Natural RNA dependent RNA polymerase inhibitors: Molecular docking studies of some biologically active alkaloids of Argemone mexicana

June 01, 2020 - COVID-19 has become disastrous for world and spread all over. Researchers all around the globe are working to discover a drug to cure from COVID-19

 

Two linear epitopes on the SARS-CoV-2 spike protein that elicit neutralising antibodies in COVID-19 patients

June 01, 2020 - Given the ongoing SARS-CoV-2 pandemic, identification of immunogenic targets against the coronavirus spike glycoprotein will provide crucial advances towards the development of sensitive diagnostic

 

Immune response in COVID-19: addressing a pharmacological challenge by targeting pathways triggered by SARS-CoV-2

May 29, 2020 - To date, no vaccines or effective drugs have been approved to prevent or treat COVID-19 and the current standard care relies on supportive treatments

 

Potentially repurposable drugs for COVID-19 identified from SARS-CoV-2 Host Protein Interactome

May 28, 2020 - We previously presented the protein-protein interaction network (‘HoP Interactome’) of 332 host proteins that were identified to interact with 27 nCoV19 viral proteins by Gordon et al

 

Lopinavir-ritonavir versus hydroxychloroquine for viral clearance and clinical improvement in patients with mild to moderate coronavirus disease 2019

May 27, 2020 - The efficacies of lopinavir-ritonavir or hydroxychloroquine remain to be determined in patients with coronavirus disease 2019 (COVID-19

 

Remdesivir for 5 or 10 Days in Patients with Severe Covid-19

May 27, 2020 - Remdesivir is an RNA polymerase inhibitor with potent antiviral activity in vitro and efficacy in animal models of coronavirus disease 2019 (Covid-19)

 

Evaluation of the efficacy and safety of intravenous remdesivir in adult patients with severe COVID-19: study protocol for a phase 3 randomized, double-blind, placebo-controlled, multicentre trial

May 24, 2020 - Coronavirus disease 2019 (COVID-19), caused by a novel corinavirus (later named SARS-CoV-2 virus), was fistly reported in Wuhan, Hubei Province, China towards the end of 2019. 

 

A human neutralizing antibody targets the receptor binding site of SARS-CoV-2

May 22, 2020 - An outbreak of the coronavirus disease 2019 (COVID-19)1–3, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)4 spread globally

 

Remdesivir for the Treatment of Covid-19 — Preliminary Report

May 22, 2020 - Although several therapeutic agents have been evaluated for the treatment of coronavirus disease 2019 (Covid-19), none have yet been shown to be efficacious

 

Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis

May 22, 2020 - Often in combination with a second-generation macrolide, are being widely used for treatment of COVID-19, despite no conclusive evidence of their benefit

 

No Benefit for Lopinavir–Ritonavir in Severe COVID-19

May 21, 2020 - Treatment with the HIV combination drug lopinavir-ritonavir did not accelerate recovery or improve mortality rates among hospitalized patients with severe coronavirus disease 2019 (COVID-19), a trial in the New England Journal of Medicine reported.

 

Beximco Pharma introduces world’s first generic remdesivir for COVID-19 treatment

May 21, 2020 -Beximco Pharmaceuticals Limited (“Beximco Pharma”, “BPL” or “the Company”), the fast-growing manufacturer of generic pharmaceutical products and active pharmaceutical ingredients, announces the launch of remdesivir (under the brand name Bemsivir), an antiviral drug, which has been recently granted Emergency Use Authorization by the U.S. Food and Drug Administration for the treatment of COVID-19

 

An in-silico approach to develop of a multi-epitope vaccine candidate against SARS-CoV-2 envelope (E) protein

May 20, 2020 - Since the rst appearance of the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS- CoV-2) in China on December 2019, the world has now witnessed the emergence of the SARS- CoV-2 outbreak 

 

Immunogenicity of a DNA vaccine candidate for COVID-19

May 20, 2020 - The coronavirus family member, SARS-CoV-2 has been identified as the causal agent for the pandemic viral pneumonia disease, COVID-19

 

Ministério da Saúde divulga diretrizes para tratamento medicamentoso de pacientes

20.05.2020 - As recomendações publicadas nesta quarta-feira (20) são para o tratamento precoce, com cloroquina e hidroxicloroquina, de pacientes com COVID-19, no Sistema Único da Saúde (SUS) 

 

Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody

May 18, 2020 - SARS-CoV-2 is a newly emerged coronavirus responsible for the current COVID-19 pandemic that has resulted in more than 3.7 million infections and 260,000 deaths as of 6 May 2020 

 

Proteomics of SARS-CoV-2-infected host cells reveals therapy targets

May 14, 2020 - A novel coronavirus was recently discovered and termed SARS-CoV-2. Human infection can cause coronavirus disease 2019 (COVID-19), which has been rapidly spreading around the globe1,2

 

JAK Inhibition as a New Treatment Strategy for Patients with COVID-19

May 11, 2020 - After the advent of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the outbreak of coronavirus disease 2019 (COVID-19) commenced across the world

 

An Update on Current Therapeutic Drugs Treating COVID-19

May 11, 2020 - The current pandemic of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has presented unprecedented challenges to the healthcare systems in almost every country around the world

 

Association of Treatment With Hydroxychloroquine or Azithromycin With In-Hospital Mortality in Patients With COVID-19 in New York State

May 11, 2020 - Among patients with coronavirus disease 2019 (COVID-19), is there an association between use of hydroxychloroquine, with or without azithromycin, and in-hospital mortality?

 

Triple combination of interferon beta-1b, lopinavir–ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial

May 08, 2020 - Effective antiviral therapy is important for tackling the coronavirus disease 2019 (COVID-19) pandemic. We assessed the efficacy and safety of combined interferon beta-1b, lopinavir–ritonavir, and ribavirin for treating patients with COVID-19

 

The COVID-19 Gene and Drug Set Library

May 06, 2020 - The coronavirus (CoV) severe acute respiratory syndrome (SARS)-CoV-2 (COVID-19) pandemic has received rapid response by the research community to offer suggestions for repurposing of approved drugs as well as to improve our understanding of the COVID-19 viral life cycle molecular

 

Coronavirus (COVID-19) Update: FDA Issues Emergency Use Authorization for Potential COVID-19 Treatment

May 01, 2020 - Today, the U.S. Food and Drug Administration issued an emergency use authorization for the investigational antiviral drug remdesivir for the treatment of suspected or laboratory-confirmed COVID-19 in adults and children hospitalized with severe disease


Identification of new drug treatments to combat COVID19: A signature-based approach using iLINCS

April 30, 2020 - The COVID-19 pandemic caused by the novel SARS-CoV-2 is more contagious than other coronaviruses and has higher rates of mortality than influenza

 

EMA starts rolling review of remdesivir for COVID-19

April 30, 2020 - EMA’s human medicines committee (CHMP) has started a ‘rolling review’ of data on the use of the investigational antiviral medicine remdesivir for the treatment of coronavirus disease (COVID-19)

 

Plataforma reúne gráficos interativos sobre a evolução da COVID-19 no Brasil

30.04.2020 - Os gráficos mostram a quantidade total de casos e óbitos confirmados, a incidência na população, a taxa de letalidade e o número de novos casos

 

Hopes rise for coronavirus drug remdesivir

April 29, 2020 - Despite conflicting studies, results from largest trial yet show the antiviral speeds up recovery, putting it on track to become a standard of care in the United States

 

Covid-19 Drugs & Vaccines Tracker

April, 2020 - In the months since the novel coronavirus rose from a regional crisis to a global threat, drug makers large and small have scrambled to advance their best ideas for thwarting a pandemic

 

COVID-19 Resource Centre

April 25, 2020 - To assist health workers and researchers working under challenging conditions to bring this outbreak to a close, The Lancet has created a Coronavirus Resource Centre. This resource brings together new 2019 novel coronavirus disease (COVID-19) content from across The Lancet journals as it is published. All of our COVID-19 content is free to access

 

Covid-19 Arrived in Seattle. Where It Went From There Stunned the Scientists

April 22, 2020 - As the coronavirus outbreak consumed the city of Wuhan in China, new cases of the virus began to spread out like sparks flung from a fire

 

Información técnica, precios y registros sanitarios de pruebas diagnósticas para detección del virus SARS-CoV-2 en 5 países de América Latina y otras regiones

Abil de 2020 - Información técnica, precios y registros sanitarios de pruebas diagnósticas para detección del virus SARS-CoV-2 en 5 países de América Latina y otras regiones

 

Exceptional GMP flexibilities for medicines manufacturers during the coronavirus (COVID-19) outbreak

April 22, 2020 - These temporary good manufacturing practice (GMP) flexibilities will be allowed to address the current exceptional circumstances

 

Connecting clusters of COVID-19: an epidemiological and serological investigation

April 21, 2020 - Elucidation of the chain of disease transmission and identification of the source of coronavirus disease 2019 (COVID-19) infections are crucial for effective disease containment

 

Coronavirus Infections May Not Be Uncommon, Tests Suggest

April 21, 2020 - Two preliminary efforts to survey citizens for antibodies to the virus have produced controversial results

 

Developing therapeutic monoclonal antibodies at pandemic pace

April 21, 2020 -The time from discovery to proof-of-concept trials could be reduced to 5–6 months from a traditional timeline of 10–12 months

 

Coronavirus (COVID-19) Update: FDA Authorizes First Test for Patient At-Home Sample Collection

April 21, 2020 - The U.S. Food and Drug Administration authorized the first diagnostic test with a home collection option for COVID-19

 

Launch of enhanced monitoring system for availability of medicines used for treating COVID-19

April 21, 2020 - EMA, together with the pharmaceutical industry and the EU Member States, has launched its enhanced fast-track monitoring system to help prevent and mitigate supply issues with crucial medicines used for treating patients with COVID-19

 

Update to guidance on regulatory expectations in the context of COVID-19 pandemic 

April 20, 2020 - The European Commission, EMA and the national competent authorities have agreed a series of measures to mitigate the impact of disruptions caused by COVID-19 on the conduct0 of inspections of manufacturing facilities or other sites relevant for medicinal products in the European Union

 

Recent progress and challenges in drug development against COVID-19 coronavirus (SARS-CoV-2) - an update on the status

April 19, 2020 - Coronaviruses are a large group of viruses known to cause illnesses that vary between the common cold and more severe diseases to include severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS)

 

NIH to launch public-private partnership to speed COVID-19 vaccine and treatment options

April 17, 2020 - The National Institutes of Health and the Foundation for the NIH (FNIH) are bringing together more than a dozen leading biopharmaceutical companies, the Health and Human Services Office of the Assistant Secretary for Preparedness and Response, the Centers for Disease Control and Prevention, the U.S.

 

Immunity from COVID-19 antibodies not certain, HIV co-discoverer cautions

April 14, 2020 - The race is on to develop and distribute antibody tests for the coronavirus, driven by the idea that these tests will inform individuals when they are immune to the virus and can return to their normal lives

 

Drug Evaluation during the Covid-19 Pandemic

April 14, 2020 - The search for a treatment for Covid-19 is testing our country’s ability to quickly develop, test, and deploy medications, presenting both opportunities and challenges to our drug-assessment apparatus

 

Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19)

April 13, 2020 - The pandemic of coronavirus disease 2019 (COVID-19) caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) presents an unprecedented challenge to identify effective drugs for prevention and treatment

 

Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19)

April 13, 2020 - The pandemic of coronavirus disease 2019 (COVID-19) caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) presents an unprecedented challenge to identify effective drugs for prevention and treatment

 

Trade set to plunge as COVID-19 pandemic upends global economy

April 13, 2020 - World trade is expected to fall by between 13% and 32% in 2020 as the COVID 19 pandemic disrupts normal economic activity and life around the world

 

Update on EU actions to support availability of medicines during COVID-19 pandemic

April 10, 2020 - The continued availability of medicines is one of the most important priorities for EU authorities that are adopting measures to mitigate possible disruptions to the supply of medicines caused by the ongoing COVID-19 pandemic

 

Compassionate Use of Remdesivir for Patients with Severe Covid-19

April 10, 2020 -O remdesivir, um pró-fármaco análogo de nucleotídeo que inibe a polimerase de RNA viral, demonstrou atividade in vitro contra SARS-CoV-2

 

COVID-19 and risks to the supply and quality of tests, drugs, and vaccines

April 09, 2020 - Emergency efforts are underway to find optimum medical products to prevent infection and diagnose and treat patients during the coronavirus disease 2019 (COVID-19) pandemic

 

Structure of Mpro from COVID-19 virus and discovery of its inhibitors

April 09, 2020 - A new coronavirus (CoV) identified as COVID-19 virus is the etiological agent responsible for the 2019-2020 viral pneumonia outbreak that commenced in Wuhan

 

Treatment options for COVID-19: The reality and challenges

April 04, 2020 - An outbreak related to the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was first reported in Wuhan, China in December 2019

 

Situação patentária de produtos passíveis para uso contra à Covid-19

09.04.2020 - Dando prosseguimento ao estudo sobre possíveis moléculas e produtos para tratamento e prevenção da COVID-19, após os estudos elaborados a partir das informações obtidas no estudo publicado pela American Chemical Society , a ABIFINA traz um levantamento das patentes correspondentes brasileiras de produtos já comercializados para prevenção e tratamento de outras doenças que possam ser utilizados para prevenção e tratamento de COVID-19

 

Global regulators stress need for robust evidence on COVID-19 treatments

April 09, 2020 - International regulators have published a report today highlighting their considerations on the development of potential COVID-19 therapeutics, clinical trials and compassionate use programmes

 

BMJ's Coronavirus (covid-19) Hub

April 09, 2020 -BMJ's covid-19 hub supports health professionals and researchers with practical guidance, online CPD courses, as well as the latest news, comment, and research from The BMJ.

 

Situação patentária de vacinas relacionadas à Covid-19

08.04.2020 - Dando prosseguimento ao estudo sobre possíveis moléculas para tratamento e prevenção da COVID-19, a partir das informações obtidas no estudo publicado pela American Chemical Society , a ABIFINA traz um levantamento das patentes correspondentes brasileiras de vacinas que possam ser utilizadas na pandemia de COVID-19

 

Global regulators discuss observational studies of real world data for COVID-19 medicines 

April 07, 2020 - In a dedicated COVID-19 workshop, organised by the European Medicines Agency (EMA) under the umbrella of the International Coalition of Medicines Regulatory Authorities (ICMRA), international regulators discussed how data generated during clinical practice could complement evidence from clinical trials with potential therapeutics or vaccines against COVID-19

 

Atazanavir inhibits SARS-CoV-2 replication and pro-inflammatory cytokine production

April 07, 2020 - Besides social isolation, identification of the suitable clinically approved drugs to be repurposed could lead to short-term action to reduce mortality

 

Open for outbreaks

April 07, 2020 - In the onslaught of the COVID-19 pandemic, the open sharing of materials, information and data is gaining increasing importance in biotech.

 

Coalition launched to accelerate research on the prevention and treatment of COVID-19 in low- and middle-income countries

April 03, 2020 - A group of scientists, physicians, funders, and policy makers from over 70 institutions from over 30 countries have launched an international coalition to respond to COVID-19 in resource-poor settings

 

EMA provides recommendations on compassionate use of remdesivir for COVID-19

April 03, 2020 - During an extraordinary virtual meeting held on 2 April 2020, EMA’s human medicines committee (CHMP) gave recommendations on how the investigational antiviral medicine remdesivir should be used for treating coronavirus disease (COVID-19) in compassionate use programmes in the European Union

 

International regulators discuss available knowledge supporting COVID-19 medicine development

April 03, 2020 - On 2 April, regulators from around the world joined the second workshop on COVID-19 organised by the European Medicines Agency (EMA) under the umbrella of the International Coalition of Medicines Regulatory Authorities (ICMRA)

 

Systematic review of the efficacy and safety of antiretroviral drugs against SARS, MERS, or COVID‐19: initial assessment

April 02, 2020 - Several antiretroviral drugs are being considered the treatment of COVID‐19, the disease caused by a newly identified coronavirus, (SARS‐CoV‐2).

 

HHS accepts donations of medicine to Strategic National Stockpile as possible treatments for COVID-19 patients

April 02, 2020 - FDA issues emergency use authorization for donated hydroxychloroquine sulfate, chloroquine phosphate

 

Coronavirus disease (COVID-2019) R&D

April 02, 2020 - On 31 December 2019, WHO was informed of a cluster of cases of pneumonia of unknown cause detected in Wuhan City, Hubei Province of China

 

Optimizing the Trade-off Between Learning and Doing in a Pandemic

April 02, 2020 - The world is united regarding the goal of ending the coronavirus disease 2019 (COVID-19) pandemic but not the strategy to achieve that goal

 

COVID-19: combining antiviral and anti-inflammatory treatments

April 01, 2020 - Both coronavirus disease 2019 (COVID-19) and severe acute respiratory syndrome (SARS) are characterised by an overexuberant inflammatory response and, for SARS, viral load is not correlated with the worsening of symptoms

 

Renin–Angiotensin–Aldosterone System Inhibitors in Patients with Covid-19

March 30, 2020 - The renin–angiotensin– aldosterone system (RAAS) is an elegant cascade of vasoactive peptides that orchestrate key processes in human physiology.

 

NOTA INFORMATIVA Nº 5/2020-DAF/SCTIE/MS

27.03.2020 - Uso da Cloroquina como terapia adjuvante no tratamento de formas graves do COVID-19

 

Use of antiviral drugs to reduce COVID-19 transmission 

March 27, 2020 - As the coronavirus disease 2019 (COVID-19) spreads, efforts are being made to reduce transmission via standard public health interventions based on isolation of cases and tracing of contacts.

 

EMA advises continued use of medicines for hypertension, heart or kidney disease during COVID-19 pandemic

March 27, 2020 - EMA is aware of recent media reports and publications which question whether some medicines, for instance angiotensin converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs, or sartan medicines), could worsen coronavirus disease (COVID-19)

 

Exportação de cloroquina e azitromicina: veja a RDC 352

March 27, 2020 - De acordo com a Resolução da Diretoria Colegiada 352, a exportação necessitará temporariamente de autorização prévia da Anvisa.

 

Situação patentária de moléculas e composições relacionadas à Covid-19

25.03.2020 - Diante da pandemia da COVID-19, e a partir das informações obtidas por um estudo publicado pela American Chemical Society , a ABIFINA fez um levantamento preliminar das patentes brasileiras correspondentes para as moléculas que estão sendo estudadas para prevenção e/ou tratamento da COVID-19. 

 

Gilead Declines 'Rare Disease' Status For Experimental Coronavirus Drug

March 26, 2020 - In a surprising turnabout, drugmaker Gilead Sciences asked the Food and Drug administration on Wednesday to rescind orphan status for remdesivir, the company's experimental coronavirus treatment

 

India bans exports of drug touted by Trump as potential Covid-19 treatment

March 26, 2020 - Amendment in Export Policy of Hydroxychloroquine

 

Global regulatory workshop on COVID-19 vaccine development

March 25, 2020 - A virtual meeting, held under the umbrella of the International Coalition of Medicines Regulatory Authorities (ICMRA), convening experts from medicines regulatory authorities, the World Health Organisation (WHO) and the European Commission 

 

Comparison of Lopinavir/Ritonavir or Hydroxychloroquine in Patients With Mild Coronavirus Disease (COVID-19)

March 25, 2020 - In vitro studies revealed that lopinavir/ritonavir and hydroxychloroquine have antiviral activity against Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)

 

The Official Chinese Government Guide to Diagnosing and Treating the Novel Coronavirus

March 25, 2020 - You may not have heard of it. It’s now on version 7. You should read it.

 

Resources and Use of Approved Therapies for Treatment of n-CoViD-19 Disease

March 2020 - Therapies Approved by US FDA for Other Conditions

 

Insights from nanomedicine into chloroquine efficacy against COVID-19

March 23, 2020 - Chloroquine — an approved malaria drug — is known in nanomedicine research for the investigation of nanoparticle uptake in cells, and may have potential for the treatment of COVID-19

 

FDA and EMA Collaborate to Facilitate SARS-CoV-2 Vaccine Development

March 23, 2020 - Vaccines offer a way to build immunity to a disease-causing microorganism before one has ever been exposed to it. They have been highly effective in preventing a whole range of serious infectious diseases

 

The first study of a potential coronavirus vaccine will soon start recruiting healthy volunteers in Georgia at Emory University

Mar 23, 2020 - A pharmacist gives Jennifer Haller, left, the first shot in the first-stage safety study clinical trial of a potential vaccine for COVID-19, the disease caused by the new coronavirus, Monday, March 16, 2020, at the Kaiser Permanente Washington Health Research Institute in Seattle. 

 

Genentech Announces FDA Approval of Clinical Trial for Actemra to Treat Hospitalized Patients With Severe COVID-19 Pneumonia

March 23, 2020 - Genentech will also provide 10,000 vials of Actemra to the U.S. Strategic National Stockpile. Current U.S. supply of Actemra for approved indications is not expected to be impacted 

 

WHO launches global megatrial of the four most promising coronavirus treatments

Mar. 22, 2020 - Could any of these drugs hold the key to saving coronavirus disease 2019 (COVID-19) patients from serious harm or death? On Friday, the World Health Organization (WHO) announced a large global trial, called SOLIDARITY, to find out whether any can treat infections with the new coronavirus for the dangerous respiratory disease. 

 

The pandemic pipeline

20 March 2020 - Companies are doing their best to accelerate experimental drugs and vaccines for COVID-19 through the pipeline. Each faces its own set of challenges, but all agree on the need for a radical rethink of the clinical development process for pandemics. 

 

The pandemic pipeline

20 March 2020 - Companies are doing their best to accelerate experimental drugs and vaccines for COVID-19 through the pipeline. Each faces its own set of challenges, but all agree on the need for a radical rethink of the clinical development process for pandemics. 

 

Chloroquine, Past and Present

20 March, 2020 - Derek Lowe's commentary on drug discovery and the pharma industry. An editorially independent blog from the publishers of Science Translational Medicine. All content is Derek’s own, and he does not in any way speak for his employer.

 

A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19

March 18, 2020 - No therapeutics have yet been proven effective for the treatment of severe illness caused by SARS-CoV-2

 

Sanofi, Regeneron test arthritis drug against COVID-19

March 18, 2020 - New study explores whether dampening IL-6 could address serious coronavirus infections 

 

Chilean Chamber of Deputies approves resolution for compulsory licenses for patents relating to the coronavirus virus

March 17, 2020 - Today, with an overwhelming 127 votes in favor and 0 votes against, the Chilean Chamber of Deputies approved a strong resolution asking the Chilean Government to declare that there is justification for compulsory licenses for vaccines, drugs, diagnostics, devices, supplies, and other technologies useful for the surveillance, prevention, detection, diagnosis and treatment of people infected by the coronavirus virus in Chile.

 

Hydroxychloroquine would be effective, according to Professor Raoult of the IHU in Marseille, after a first limited test

March 17, 2020 - Professor Didier Raoult, director of the IHU in Marseille, presented the first results of the hydroxychloroquine clinical test carried out on 24 patients suffering from coronavirus.

 

Substantial undocumented infection facilitates the rapid dissemination of novel coronavirus

16 March 2020 - Estimation of the prevalence and contagiousness of undocumented novel coronavirus (SARS-CoV2) infections is critical for understanding the overall prevalence and pandemic potential of this disease.

 

Research and Development on Therapeutic Agents and Vaccines for COVID-19 and Related Human Coronavirus Diseases

March 12, 2020 - Since the outbreak of the novel coronavirus disease COVID-19, caused by the SARS-CoV-2 virus, this disease has spread rapidly around the globe. Considering the potential threat of a pandemic, scientists and physicians have been racing to understand this new virus and the pathophysiology of this disease to uncover possible treatment regimens and discover effective therapeutic agents and vaccine